Bacterial and Tuberculous Infections of Nervous System DRG

DRG 094 addresses bacterial and tuberculous infections of the nervous system accompanied by Major Complication or Comorbidity; it captures high-acuity cases that demand intensive inpatient care. Correct DRG assignment affects Medicare payments because the Major Complication or Comorbidity designation increases expected resource intensity and reimbursement.

DRG 094 Overview

DRG 094 covers hospital admissions for bacterial and tuberculous infections of the nervous system that include a Major Complication or Comorbidity, such as severe sepsis, intracranial abscess with neurologic deterioration, or other life-threatening systemic complications. These cases typically require intensive medical management, prolonged antimicrobial therapy, potential neurosurgical intervention, and extended inpatient monitoring. This Diagnosis-Related Group is important for Medicare payment because the presence of a Major Complication or Comorbidity increases resource use and drives higher reimbursement relative to cases without such severity.

Acute antimicrobial therapy optimization trials: studies comparing different intravenous antibiotic regimens, dosing strategies, or duration of therapy for patients hospitalized with bacterial meningitis or tuberculous meningitis who present with severe manifestations and major complications (for example, sepsis, intracranial abscess, hydrocephalus, or need for ICU support). These trials enroll acutely ill adults and children within the inpatient setting to evaluate time to sterilization of cerebrospinal fluid, neurologic complication rates, and short-term mortality; results inform frontline clinicians about effective, rapid regimens and help payers assess cost-effectiveness of inpatient antimicrobial choices and lengths of stay. This research is relevant because prompt appropriate therapy and optimized dosing can reduce MCC-related morbidity, ICU utilization, and downstream costs associated with prolonged hospitalization and rehabilitation.
Comparative effectiveness studies of adjunctive interventions in complicated central nervous system infections: pragmatic trials or observational cohort studies testing adjunctive strategies such as corticosteroids, intracranial pressure management protocols, neurosurgical drainage techniques, or implementation of standardized sepsis pathways in patients with bacterial or tuberculous infections of the nervous system complicated by abscess, elevated intracranial pressure, or neurologic deterioration. These studies focus on heterogeneous inpatient populations with major complications to determine which adjuncts reduce neurologic sequelae, need for repeat surgery, or inpatient mortality, and they often measure resource use (ICU days, imaging, procedures) alongside clinical outcomes. Findings guide hospital protocols and resource allocation decisions important to providers managing complex cases and to payers evaluating value and reimbursement for bundled inpatient care.
Post-discharge functional outcomes and readmission prevention research: longitudinal cohort studies and intervention trials that follow survivors of severe CNS bacterial or tuberculous infections with major complications to evaluate rehabilitation needs, cognitive and functional recovery, rates and causes of 30- and 90-day readmissions, and the effectiveness of care-transition interventions (early outpatient follow-up, structured home health, or telemedicine monitoring). These studies enroll patients discharged after complicated inpatient courses and assess quality of life, long-term neurologic disability, and healthcare utilization; they are critical for designing post-acute care pathways, estimating long-term costs, and informing payers and providers about interventions that reduce readmissions and improve recovery trajectories for this high-risk DRG population.

Acute antimicrobial therapy optimization trials: studies comparing different intravenous antibiotic regimens, dosing strategies, or duration of therapy for patients hospitalized with bacterial meningitis or tuberculous meningitis who present with severe manifestations and major complications (for example, sepsis, intracranial abscess, hydrocephalus, or need for ICU support). These trials enroll acutely ill adults and children within the inpatient setting to evaluate time to sterilization of cerebrospinal fluid, neurologic complication rates, and short-term mortality; results inform frontline clinicians about effective, rapid regimens and help payers assess cost-effectiveness of inpatient antimicrobial choices and lengths of stay. This research is relevant because prompt appropriate therapy and optimized dosing can reduce MCC-related morbidity, ICU utilization, and downstream costs associated with prolonged hospitalization and rehabilitation.
Comparative effectiveness studies of adjunctive interventions in complicated central nervous system infections: pragmatic trials or observational cohort studies testing adjunctive strategies such as corticosteroids, intracranial pressure management protocols, neurosurgical drainage techniques, or implementation of standardized sepsis pathways in patients with bacterial or tuberculous infections of the nervous system complicated by abscess, elevated intracranial pressure, or neurologic deterioration. These studies focus on heterogeneous inpatient populations with major complications to determine which adjuncts reduce neurologic sequelae, need for repeat surgery, or inpatient mortality, and they often measure resource use (ICU days, imaging, procedures) alongside clinical outcomes. Findings guide hospital protocols and resource allocation decisions important to providers managing complex cases and to payers evaluating value and reimbursement for bundled inpatient care.
Post-discharge functional outcomes and readmission prevention research: longitudinal cohort studies and intervention trials that follow survivors of severe CNS bacterial or tuberculous infections with major complications to evaluate rehabilitation needs, cognitive and functional recovery, rates and causes of 30- and 90-day readmissions, and the effectiveness of care-transition interventions (early outpatient follow-up, structured home health, or telemedicine monitoring). These studies enroll patients discharged after complicated inpatient courses and assess quality of life, long-term neurologic disability, and healthcare utilization; they are critical for designing post-acute care pathways, estimating long-term costs, and informing payers and providers about interventions that reduce readmissions and improve recovery trajectories for this high-risk DRG population.

OpenPayer

Summary & Overview

Bacterial and Tuberculous Infections of Nervous System with MCC: Inpatient Reimbursement Overview

DRG 094 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes